Patents Assigned to Biologics, Inc.
  • Compositions containing protein loaded exosome and methods for preparing and delivering the same
    Publication number: 20200289614
    Abstract: The present invention relates to a method for the mass-production of exosome comprising a cargo protein, a vector for preparing the exosome, exosome including a cargo protein prepared by the method, and a method for loading the cargo protein to cytosol by using the exosome prepared thereby. According to the method for preparing an exosome comprising a cargo protein provided by the present invention, the exosome loaded with a cargo protein can be produced with a high yield, so that it can be used broadly in the treatment of disease using the exosome.
    Type: Application
    Filed: May 29, 2020
    Publication date: September 17, 2020
    Applicant: ILIAS BIOLOGICS INC.
    Inventors: Chulhee CHOI, Nambin YIM, Won Do HEO, Seung-Wook RYU, Hojun CHOI, Kyungsun CHOI
  • System for delivery of microbial inoculants and related materials and methods
    Patent number: 10774298
    Abstract: Described herein are systems, methods and kits for culturing and applying fresh microbial inoculants in the field. The system, methods and kits are easy to use, reliable, sealed to prevent contamination, and can be stored on location, for use on demand by those unskilled in the microbiological arts. Particular embodiments described herein may be used to increase agricultural crop yields.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: September 15, 2020
    Assignees: 3BAR BIOLOGICS, INC., OHIO STATE INNOVATION FOUNDATION
    Inventors: Bruce H. Caldwell, Brian B. McSpadden Gardener
  • Antimitotic amides for the treatment of cancer and proliferative disorders
    Patent number: 10772872
    Abstract: Novel, antimitotic heteroaryl amides and pharmaceutically acceptable salts of Formula I where Ar, R5, R6, R8, R9, R11, X1, and X2 are as defined herein, as compounds for treatment and prevention of cancer and proliferative diseases and disorders.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 15, 2020
    Assignee: Frost Biologic, Inc.
    Inventor: Adam Siddiqui-Jain
  • Beta-lactamases with improved properties for therapy
    Patent number: 10767171
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: September 8, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • Vector co-expressing vaccine and costimulatory molecules
    Patent number: 10758611
    Abstract: Compositions and methods for co-expressing a secretable vaccine protein (such as gp96-Ig) and T-cell co-stimulatory molecules from a single vector, among others, are provided herein. Materials and methods for using gp96-Ig vaccination and T-cell co-stimulation to treat a clinical condition (e.g., cancer) in a subject also are provided.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: September 1, 2020
    Assignee: Heat Biologics, Inc.
    Inventors: Taylor Schreiber, George Fromm
  • DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof
    Patent number: 10752674
    Abstract: The present disclosure relates to a method of obtaining a cell where fucosylation pathways are modified, leading to production of partially fucosylated and non-fucosylated protein products, specifically antibodies from the cell. The present disclosure employs the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. The method of the present disclosure targets the Fut8 gene and GMD gene in a cell. Such products are used in developing therapeutics and biomarkers, and in diagnosis and prognosis of diseases.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: August 25, 2020
    Assignee: Zumutor Biologics Inc.
    Inventors: Bhargav Prasad, Divya Unnikrishnan, Jahnabi Hazarika, Kavitha Iyer Rodrigues, Maloy Ghosh, Pavithra M, Pravin Kumar D, Sanghamitra Bhattacharjee, Sathyabalan M, Sankaranarayanan Srinivasan, Sohang Chatterjee, Sunit Maity, Veeresha K, Vivek Halan, Yogendra Manjunath B. M., Anuradha Hora, Bairavabalakumar N, Karthika Nair, Aswini Thanigaivel, Amol Maliwalave, Bharath R Shenoy, Rajeshwari Pendse, Prabhat Kumar Pathak, Anisha Kurup, Sahana Bhima Rao
  • Vaccine compositions and methods
    Patent number: 10751372
    Abstract: The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: August 25, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Th1 vaccination priming for active immunotherapy
    Patent number: 10744158
    Abstract: The present invention includes vaccine compositions and methods for using these vaccine compositions in active immunotherapy. The vaccine compositions include allogeneic activated Th1 memory cells. The compositions can also include one or more disease-related antigens. The methods include administering the vaccine compositions to provide a Th1 footprint in normal individuals or patients susceptible to disease or having minimal residual disease.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: August 18, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • Anti-methanogenic lovastatin analogs or derivatives and uses thereof
    Patent number: 10736871
    Abstract: The present invention relates to, in part, methods for the treatment of methanogen-associated disorders such as, for example, Irritable Bowel Syndrome (IBS) using at least one anti-methanogenic lovastatin analog or derivative. In addition, modified-release formulations comprising at least one anti-methanogenic lovastatin analog or derivative are provided which release the anti-methanogenic lovastatin analog or derivative in the gastrointestinal tract.
    Type: Grant
    Filed: March 31, 2016
    Date of Patent: August 11, 2020
    Assignees: Cedars-Sinai Medical Center, Synthetic Biologics, Inc.
    Inventors: Mark Pimentel, Vince Wacher
  • Cell washing using acoustic waves
    Patent number: 10737012
    Abstract: Disclosed is a device for separating a cellular component from a multicomponent fluid. The device can include a body, a first acoustic wave generator, and a second acoustic wave propagating component. The body can define a channel having a first surface, an opposing second surface, a first side, and an opposing second side. The channel can extend along a longitudinal axis from a first end to an opposing second end. The first acoustic wave generator can be coupled to the first surface. The second acoustic wave propagating component can be coupled to the second surface. The first acoustic wave generator and second acoustic wave propagating component can be configured to generate a bulk standing acoustic wave in the channel.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: August 11, 2020
    Assignee: Biomet Biologics, Inc.
    Inventors: Michael D. Leach, Ned M. Hamman, David Abeskaron, Grant Cunningham, Randel Dorian, Richard Wood Storrs, Scott R. King
  • Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
    Patent number: 10729754
    Abstract: Methods of treating a patient with human immunodeficiency virus are disclosed. The method includes a providing intradermal and intravenous doses of a aTh1 composition that can increase the CD4+ cells in a patient that are resistant to HIV. The description includes a method for viral load reduction and a viral purge method. The regimen leads to a spike in the viral load and a then a return to baseline or lower levels of the virus and can lead to reduction and/or elimination of the latent viral reservoirs. Kits configured to provide intradermal doses and intravenous doses according to the regimen are also included.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: August 4, 2020
    Assignee: MIRROR BIOLOGICS, INC.
    Inventor: Michael Har-Noy
  • PREVENTION AND TREATMENT OF CORONAVIRUS AND OTHER RESPIRATORY INFECTIONS USING NANOEMULSION COMPOSITIONS
    Publication number: 20200237689
    Abstract: The present disclosure relates to nanoemulsion compositions with certain surfactant blend ratios that impart enhanced permeability. Such compositions are useful for mucosal and intranasal applications and allow for the greater delivery of one or more active agents to the application site to prevent infection by coronavirus.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 30, 2020
    Applicant: Bluewillow Biologics, Inc.
    Inventors: David Peralta, Susan Ciotti
  • fusion protein and construction method and use thereof
    Patent number: 10716847
    Abstract: Provided are a fusion protein and a construction method thereof. The fusion method consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: July 21, 2020
    Assignee: CANSINO BIOLOGICS INC.
    Inventors: Junqiang Li, Danqing Miao, Mingming Yang, Zhongqi Shao, Tao Zhu, Xuefeng Yu
  • Safe and effective beta-lactamase dosing for microbiome protection
    Patent number: 10709773
    Abstract: The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: July 14, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventor: Joseph Sliman
  • Cell culture medium
    Patent number: 10703800
    Abstract: Provided herein, inter alia, are compositions and methods for culturing mammalian cells. In certain aspects, the composition is a medium containing one or more of a lithium ion source, one or more fatty acids, and/or ethanol. Use of any of the cell culture media described herein to culture cells that have been genetically engineered to produce one or more recombinant polypeptides (for example, antibodies) can result in increased titers, a more favorable glycosylation profile, and/or modulated (e.g. decreased) amounts of high and low molecular weight species, and/or modulated (e.g. decreased) amounts of acidic or basic charge variants, compared to cells cultured in a medium that does not contain one or more of a lithium ion source, one or more fatty acids, and/or ethanol.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: July 7, 2020
    Assignee: LA JOLLA BIOLOGICS, INC.
    Inventors: Christopher T. Leber, Michael W.Y. Shen, Yiwen Tao, Hugh Eugene Murray, IV
  • Compositions containing protein loaded exosome and methods for preparing and delivering the same
    Patent number: 10702581
    Abstract: The present invention relates to a method for the mass-production of exosome comprising a cargo protein, a vector for preparing the exosome, exosome including a cargo protein prepared by the method, and a method for loading the cargo protein to cytosol by using the exosome prepared thereby. According to the method for preparing an exosome comprising a cargo protein provided by the present invention, the exosome loaded with a cargo protein can be produced with a high yield, so that it can be used broadly in the treatment of disease using the exosome.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 7, 2020
    Assignee: ILIAS BIOLOGICS INC.
    Inventors: Chulhee Choi, Nambin Yim, Won Do Heo, Seung-Wook Ryu, Hojun Choi, Kyungsun Choi
  • EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAME
    Publication number: 20200206360
    Abstract: The present invention provides a method for producing an exosome that transfers an active substance specifically to a target and the exosome produced by the same; a method for delivering the active substance to the target tissue using the exosome; a pharmaceutical composition for delivery of the active substance comprising the exosome as an active ingredient; and a composition for preparing the exosome comprising an expression vector wherein the target peptide is inserted into an extracellular portion of a transmembrane protein.
    Type: Application
    Filed: August 16, 2018
    Publication date: July 2, 2020
    Applicants: ILIAS BIOLOGICS INC., ILIAS THERAPEUTICS, INC.
    Inventors: Chulhee CHOI, Nambin YIM, Hojun CHOI, Kyungsun CHOI, Seung-Wook RYU
  • Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
    Patent number: 10689443
    Abstract: This invention relates to humanized antibodies that selectively bind the 31.1 epitope on the A33 protein differentially expressed in cancers including, lung cancer, ovarian cancer, pancreas cancer, breast cancer, and colon cancer, and diagnostic and therapeutic usages.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 23, 2020
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Xue-Ping Wang, Philip M. Arlen
  • Compositions and methods for the treatment of immunodeficiency
    Patent number: 10683343
    Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: June 16, 2020
    Assignee: ADMA BIOLOGICS, INC.
    Inventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
  • CELL ENGAGING BINDING MOLECULES
    Publication number: 20200181288
    Abstract: The present disclosure is broadly concerned with the field of cancer immunotherapy. For example, the present disclosure generally related to a binding molecule comprising antibody variable light (VL) regions, variable heavy (VH) regions, constant heavy 1 (CH1) regions, and light chain constant (CL) regions that are configured to form two antigen binding Fab regions and an antigen binding Fv region so that the binding molecule binds to two different antigens.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 11, 2020
    Applicant: Y-BIOLOGICS INC.
    Inventors: Seil JANG, Bum-Chan PARK, Young Woo PARK